Everlab, the AI-powered health platform reimagining preventive care, today announced a US$10 million (AU$15 million) seed round led by global growth equity firm Left Lane Capital. The funding will accelerate Everlab’s international expansion, fuel the development of its proprietary AI healthtech platform, and support the rollout of a deeply integrated product ecosystem designed to deliver lifelong, proactive care..

Everlab，这个由人工智能驱动的健康平台，正在重新构想预防性医疗保健。该公司今日宣布，已由全球增长型股权公司Left Lane Capital领投完成了一轮1000万美元（约合1500万澳元）的种子轮融资。这笔资金将加速Everlab的国际扩张，推动其专有的人工智能健康技术平台的开发，并支持推出一个深度集成的产品生态系统，旨在提供终身的、主动的护理服务。

Chronic disease is responsible for over 70% of global deaths, yet most healthcare systems remain reactive, designed to treat illness only after it appears. While early detection and personalized intervention can save lives, they remain inaccessible for most.

慢性病导致了全球超过70%的死亡，但大多数医疗系统仍然保持被动反应模式，仅在疾病出现后才进行治疗。尽管早期发现和个性化干预可以挽救生命，但对大多数人来说仍然无法获得。

Everlab addresses this gap with a tiered membership model that combines advanced diagnostics, digital-first doctor consultations, and intelligent health insights to deliver personalized prevention at scale. Members have access to comprehensive screening services, including advanced blood testing, whole-body MRIs, DEXA scans, VO2 max, ECG, isometric strength, continuous glucose monitoring, food journal analysis, and CT coronary angiograms paired with continuous support and personalized prevention plans.

Everlab 通过分层级的会员模式填补了这一空白，该模式结合了先进的诊断技术、以数字为主的医生咨询和智能健康洞察，从而大规模地提供个性化的预防服务。会员可以享受全面的筛查服务，包括高级血液检测、全身核磁共振成像、DEXA 扫描、最大摄氧量测试、心电图、等长力量测试、连续血糖监测、饮食日记分析以及冠状动脉 CT 血管造影，并配以持续的支持和个性化的预防计划。

The flagship Protocol membership delivers year-round diagnostics and clinically guided interventions, all at a fraction of the cost of traditional care models..

旗舰级协议会员提供全年诊断和临床指导干预，所有费用仅为传统护理模式的一小部分。

At the core of Everlab’s offering is its proprietary, full-stack clinical platform: a suite of AI agents that ingest, analyze, and interpret complex health data. These agents automate clinical summaries, identify early risk markers, and recommend personalized next steps, freeing physicians from administrative overhead and enabling earlier, more precise interventions.

在Everlab提供的服务核心是其专有的全栈临床平台：一套摄取、分析和解释复杂健康数据的人工智能代理。这些代理自动完成临床摘要、识别早期风险标志，并推荐个性化的下一步措施，使医生从行政负担中解放出来，实现更早、更精确的干预。

Through integrations with national pathology and radiology networks, Everlab maintains a real-time, longitudinal health record for every member, deeply embedding the platform within the existing healthcare system..

通过与国家病理学和放射学网络的整合，Everlab 为每位成员维护了一份实时的、纵向的健康记录，将该平台深度嵌入现有的医疗保健系统中。

“We believe everyone deserves access to world-class preventive care,” said Marc Hermann, Founder and CEO of Everlab. “By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”

“我们相信每个人都应该获得世界级的预防性医疗，”Everlab创始人兼首席执行官马克·赫尔曼表示。“通过将人工智能与领先临床医生的知识相结合，我们构建了一种新型健康平台，旨在为数百万人提供更智能、更早期的医疗服务。”

Everlab’s early momentum has been significant. With tens of thousands of customers on its waitlist and growing demand across both consumer and enterprise markets, the company is on track for 20x growth this year. Its go-to-market model positions Everlab as the leading provider of high-quality, prevention-focused care..

Everlab的早期发展势头显著。其等候名单上已有数万名客户，消费者和企业市场需求不断增长，公司有望在今年实现20倍的增长。其市场推广模式使Everlab成为高品质、预防为主护理的领先提供商。

To date, Everlab has processed over 1,000,000 biomarkers through full-body health testing. Alarmingly, one in four test results are abnormal, and for 2.5% of members, findings have been life-changing—uncovering serious conditions such as blocked arteries, gastrointestinal tumors, early-stage cancers, and congenital brain abnormalities..

迄今为止，Everlab通过全身健康检测已经处理了超过1,000,000个生物标志物。令人震惊的是，四分之一的检测结果异常，其中有2.5%的会员发现了足以改变人生的情况——揭示了诸如动脉阻塞、胃肠道肿瘤、早期癌症和先天性脑部异常等严重疾病。

Beyond diagnostics, Everlab provides data-driven, personalized interventions tailored to each member’s risk profile and health goals. Results from a meta-analysis of members retested at the platform’s built-in six-month mark show that over one-third of modifiable biomarkers improved, demonstrating the tangible health impact of Everlab’s model..

除了诊断之外，Everlab还提供基于数据的个性化干预措施，根据每个成员的风险状况和健康目标量身定制。对平台内置六个月节点重新测试的成员进行的荟萃分析结果显示，超过三分之一的可改变生物标志物得到改善，证明了Everlab模式对健康的实际影响。

“Preventive care has always been a medical ideal but rarely a commercial reality,” said Laura Sillman, Principal at Left Lane Capital. “Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision. We’re excited to support them as they build a category-defining platform.”.

“预防性护理一直是医学界的理想，但很少成为商业现实，”Left Lane Capital的负责人劳拉·西尔曼说道。“Everlab已经开发出一种可扩展的产品和模式，将临床深度与软件优势和运营精度相结合。我们很兴奋能够支持他们构建一个定义类别的平台。”

With this new round of funding, Everlab will continue to grow its clinic network, expand its engineering and clinical teams, and advance its AI-powered infrastructure—laying the foundation for a global, scalable system of preventive healthcare.

通过这一新一轮融资，Everlab 将继续扩展其诊所网络，扩充其工程和临床团队，并推进其由人工智能驱动的基础设施——为全球性的、可扩展的预防性医疗体系奠定基础。

About Everlab

关于Everlab

Everlab is an AI-powered health platform delivering personalized, preventive care through advanced diagnostics, automation, and deeply integrated clinical workflows. Based in Melbourne, Everlab’s mission is to build the world’s most effective system for preventing disease and extending lifespan. For more information, visit www.everlab.com.au.

Everlab 是一个由人工智能驱动的健康平台，通过先进的诊断技术、自动化和深度整合的临床工作流程提供个性化的预防性护理。总部位于墨尔本，Everlab 的使命是建立世界上最有效的疾病预防和延长寿命的系统。欲了解更多信息，请访问 www.everlab.com.au。

About Left Lane Capital

关于左车道资本

Founded in 2019, Left Lane Capital is a New York and London-based venture capital and growth equity firm investing in high-growth internet and consumer technology businesses globally. Left Lane's mission is to partner with extraordinary entrepreneurs who create category-defining companies across growth sectors of the economy.

Left Lane Capital 成立于2019年，是一家总部位于纽约和伦敦的风险投资和成长股权公司，专注于全球高增长的互联网和消费技术领域的投资。Left Lane 的使命是与在经济快速增长领域中创建定义类别的公司的杰出企业家合作。

Select investments include Bilt Rewards, Prenuvo, Olipop, Talkiatry, Wayflyer, Hnry, Blank Street, Kittl, Evvy, and more. For more information, visit www.leftlane.com.

精选投资包括Bilt Rewards、Prenuvo、Olipop、Talkiatry、Wayflyer、Hnry、Blank Street、Kittl、Evvy等。欲了解更多信息，请访问www.leftlane.com。

Contacts

联系人

Media enquiries:

媒体查询：

United States

美国

Erin Nilsson

艾琳·尼尔森

Mike World Wide

迈克环球

[email protected]

电子邮件地址

Australia

澳大利亚

Keira Shanley

凯拉·香农

Jack Taylor PR

杰克·泰勒公关

[email protected]

电子邮件地址

Source: businesswire.com

来源：businesswire.com